MARKET

RVMD

RVMD

REVOLUTION MEDICINES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.10
-0.50
-1.69%
Closed 16:00 07/29 EDT
OPEN
30.30
PREV CLOSE
29.60
HIGH
30.77
LOW
28.89
VOLUME
377.55K
TURNOVER
--
52 WEEK HIGH
56.18
52 WEEK LOW
21.17
MARKET CAP
2.14B
P/E (TTM)
-15.1114
1D
5D
1M
3M
1Y
5Y
Where Do Hedge Funds Stand On Revolution Medicines, Inc. (RVMD)?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2...
Insider Monkey · 07/13 12:51
BRIEF-Revolution Medicines Announces Publication Of Scientific Paper Describing Novel Class Of Anti-Tumor Compounds Targeting Mtorc1
reuters.com · 06/24 21:42
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27)
Benzinga · 05/28 12:02
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
 
Benzinga · 05/18 14:05
Goldman Sachs Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $49
Goldman Sachs analyst Chris Shibutani initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $49.
Benzinga · 05/18 10:48
--Goldman Sachs Starts Revolution Medicines at Buy With $49 Price Target
MT Newswires · 05/18 07:16
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 05/17 20:32
Analysts Are Updating Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates After Its First-Quarter Results
Last week saw the newest quarterly earnings release from Revolution Medicines, Inc. ( NASDAQ:RVMD ), an important...
Simply Wall St. · 05/12 10:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RVMD. Analyze the recent business situations of REVOLUTION MEDICINES, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RVMD stock price target is 50.50 with a high estimate of 55.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 74.27M
% Owned: 101.13%
Shares Outstanding: 73.44M
TypeInstitutionsShares
Increased
51
10.20M
New
28
2.47M
Decreased
23
2.22M
Sold Out
20
1.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mark Goldsmith
Corporate Executive
Steve Kelsey
Chief Operating Officer/General Counsel
Margaret Horn
Executive Vice President
Xiaolin Wang
Lead Director/Independent Director
Alexis Borisy
Independent Director
Elizabeth Anderson
Independent Director
Neil Exter
Independent Director
Vincent Miller
Independent Director
Eric Schmidt
Independent Director
Thilo Schroeder
Independent Director
Barbara Weber
No Data
About RVMD
Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

Webull offers kinds of Revolution Medicines Inc stock information, including NASDAQ:RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.